Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial

Detalles Bibliográficos
Autores principales: Snitker, Søren, Egebjerg, Christina, Frederiksen, Marie, Sparre, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805145/
https://www.ncbi.nlm.nih.gov/pubmed/35791625
http://dx.doi.org/10.1111/dom.14809
_version_ 1784862276753293312
author Snitker, Søren
Egebjerg, Christina
Frederiksen, Marie
Sparre, Thomas
author_facet Snitker, Søren
Egebjerg, Christina
Frederiksen, Marie
Sparre, Thomas
author_sort Snitker, Søren
collection PubMed
description
format Online
Article
Text
id pubmed-9805145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-98051452023-01-06 Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial Snitker, Søren Egebjerg, Christina Frederiksen, Marie Sparre, Thomas Diabetes Obes Metab Research Letter Blackwell Publishing Ltd 2022-08-07 2022-11 /pmc/articles/PMC9805145/ /pubmed/35791625 http://dx.doi.org/10.1111/dom.14809 Text en © 2022 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Letter
Snitker, Søren
Egebjerg, Christina
Frederiksen, Marie
Sparre, Thomas
Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title_full Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title_fullStr Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title_full_unstemmed Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title_short Ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the STEP 8 phase III trial
title_sort ease‐of‐use and acceptability of the novel semaglutide 2.4 mg single‐dose pen‐injector in people with overweight or obesity in the step 8 phase iii trial
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9805145/
https://www.ncbi.nlm.nih.gov/pubmed/35791625
http://dx.doi.org/10.1111/dom.14809
work_keys_str_mv AT snitkersøren easeofuseandacceptabilityofthenovelsemaglutide24mgsingledosepeninjectorinpeoplewithoverweightorobesityinthestep8phaseiiitrial
AT egebjergchristina easeofuseandacceptabilityofthenovelsemaglutide24mgsingledosepeninjectorinpeoplewithoverweightorobesityinthestep8phaseiiitrial
AT frederiksenmarie easeofuseandacceptabilityofthenovelsemaglutide24mgsingledosepeninjectorinpeoplewithoverweightorobesityinthestep8phaseiiitrial
AT sparrethomas easeofuseandacceptabilityofthenovelsemaglutide24mgsingledosepeninjectorinpeoplewithoverweightorobesityinthestep8phaseiiitrial

Ejemplares similares